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BACKGROUND:  Pleomorphic  xanthoastrocytoma  (PXA)  classiﬁed  as  a low  Grade  (WHO  II) astrocytic  neo-
plasm. It is  known  for its  relatively  favorable  prognosis.  It most  commonly  occurs  in young  adults.
Malignant  progression  in  PXA  has been  frequently  reported  since  its  ﬁrst description  in 1979; how-
ever,  the  presentation  of  a primary  anaplastic  PXA  tumor  with  an aggressive  clinical  course  in  adults  is
rare  especially  in  the later  age  group.
CASE  DESCRIPTION:  We  present  a case  of primary  anaplastic  PXA  in  a 53  year  old male  that  manifested  with
an early  recurrence  pattern  at 9  weeks.  Treatment  performed  was  surgical  excision  and external  beam
radiotherapy.  The  aforementioned  tumor  followed  an  aggressive  clinical  course.  Tumor  cells  exhibited
the  characteristic  expression  of  GFAP  (Glial  ﬁbrillary  acidic  protein),  higher  proliferative  index  (8–10%)  on
Ki-67 staining  along  with  the  presence  of increased  mitoses  ( >5/10hpf).  A  review  of  previously  reported
primary  anaplastic  pleomorphic  xanthoastrocytoma  cases  in adults  with  histological  features  was  also
done.
CONCLUSION:  Our  review  of  all reported  cases  of APXA  in adults  concludes  that the  clinical  behavior  of this
tumor  varies  considerably  from  its benign  variant.  Early  disease  recurrence  in  anaplastic  pleomorphic
xanthoastrocytomas  is  associated  with  fatal  outcomes.  As  per  our  review  of literature  it is seen that
anaplastic  variant  of  PXA  shows  histological  characteristics  as well  as clinical  course  comparable  with
Grade  III astrocytomas.
We  recommend  further  evaluation  of PXA  with  anaplastic  features  regarding  their  genetic character-
istics  to understand  the  origin  as  well  as  behavior  of this  tumor.
©  2016  The  Authors.  Published  by  Elsevier  Ltd  on  behalf  of  IJS Publishing  Group  Ltd.  This is  an  open
access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Pleomorphic xanthoastrocytoma (PXA) is an astrocytic neo-
plasm with a relatively favorable prognosis [8]. According to WHO
classiﬁcation for astrocytic neoplasms, it has been classiﬁed his-
tologically as a grade II (benign) neoplasm [6]. The ﬁrst case
was reported in 1979 [11]. It is often superﬁcially located in the
cerebral cortex with leptomennigeal involvement. Morphologi-
cally it shows a pleomorphic histological appearance that includes
lipidized, GFAP-expressing tumor cells with cytoplasmic xanthic
change surrounded by a reticulin network [9]. It has been frequently
seen that tumors initially diagnosed as PXA have later shown malig-
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nant progression to high grade astrocytomas (grade III or IV). In
these cases the initial histological ﬁndings corresponded to a grade
II neoplasm; however over the recurrences it was found to be malig-
nant [3]. To the best of our knowledge, only a few cases have been
reported in the literature, which demonstrate a PXA tumor pre-
senting with anaplastic features at initial presentation. These cases
have been reported mostly in children and young adults ranging
between 7–25 years [16]. Here we  present a case of a primary
anaplastic PXA tumor in the later age group with an unusual early
recurrence pattern. We  then review the literature of previously
reported cases of primary anaplastic PXA tumors in adults.
2. Case description
55 years old male presented with a history of sudden onset
headaches and two episodes of generalized tonic clonic seizures in
3 months. Neurological examination did not show any focal motor
or sensory deﬁcits. MRI  brain showed a 2.2 × 1.3 × 1.1 cm nodular
http://dx.doi.org/10.1016/j.ijscr.2016.08.022
2210-2612/© 2016 The Authors. Published by Elsevier Ltd on behalf of IJS Publishing Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).
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Fig. 1. (A) MRI  Brain T1 weighted showing hypointense nodular thickening in the left temporal lobe and para sylvian ﬁssure. (B) T2 weighted image showing hyperintense
lesion  in the left temporal lobe. (C) T1 contrast image showing patchy enhancement in the left temporal lobe.
Fig. 2. MR spectroscopy showing high Choline/Creatine and high Choline/NAA ratios in the enhancing areas and persistent lactate peak in all enhancing areas favoring
neoplastic lesion.
Fig. 3. MRI  Brain showing signiﬁcant overall increase in the size of tumor involving the left frontal, temporal and parietal lobes with perilesional edema and post surgical
changes in T1, T1 post contrast and T2 weighted images respectively.
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Fig. 4. A. PXA tumor exhibiting numerous eosinophilic hyaline globule. B. Tumor showing sheets of astrocytic cells having pleomorphic nuclei with some cells having
xanthomatous cytoplasm. Presence of frequent mitoses (arrows showing two mitotic ﬁgure) 40×.  C. Tumor showing sheets of spindly to large polygonal astrocytic cells
having  pleomorphic nuclei with nuclear inclusions 40×.  D. PXA exhibiting necrosis.
thickening and enhancement along left medial temporal lobe and
sylvian ﬁssure. It appeared as a multicystic lesion with peripheral
enhancement and marked perilesional oedema (Fig. 1). MR  Spec-
troscopy showed high choline/creatine and high choline/NAA ratios
in the enhancing areas (Fig. 2). Patient underwent a left sided pte-
rional craniotomy for excision of the lesion. Gross total resection
of the tumor was performed. Immediate post operative MRI  scan
was not done due to ﬁnancial constraints. Biopsy report suggested
a neoplastic lesion composed of plump spindle-shaped pleomor-
phic cells having elongated nuclei with eosinophilic cytoplasm
and other cells having bizarre pleomorphic nuclei with abundant
cytoplasm. GFAP (glial ﬁbrillary acidic protein) immune staining
showed diffuse expression in tumor cells.Ki-67 staining showed
a proliferative index of upto 8–10% in some areas along with
the presence of increased mitoses (>5/10hpf). H & E staining also
showed a few xanthomatous cells along with areas of focal necro-
sis. CD34 immune staining was negative excluding epitheliod cell
glioblastoma (Figs. 4 and 5). Overall ﬁndings were suggestive of
an anaplastic pleomorphic xanthoastrocytoma. Case was discussed
in the tumor board meeting and external beam radiotherapy was
advised. On follow up visit patient exhibited mild to moderate cog-
nitive impairment, sensory dysphasia and disorientation. MRI  scan
was repeated 9 weeks after surgery. Repeat scan showed a signiﬁ-
cant overall increase in tumor size with both multifocal cystic and
solid components involving left frontal, temporal and parietal lobes
measuring approximately 9.6 × 5.1 × 5 cm clearly elicited disease
progression (Fig. 3). The prognosis of the patient was  discussed with
family regarding further management plan and it was decided to
continue radiotherapy and no surgical intervention was planned.
Patient died at 16 weeks from the time of initial diagnosis.
3. Discussion
PXA with anaplastic features is a rare tumor hence no deﬁni-
tive treatment guidelines have been established so far. The recent
consolidated review of literature by Tmara et al. [24] in 2012 has
reported 20 cases of primary anaplastic PXA in adults (18 above)
so far. We  report a total of 24 cases of primary APXA in adults
from 1979 to 2016. We  describe this case of primary anaplas-
tic PXA in an adult male with special regard to a rapid disease
progression only after a 9 weeks interval. To the best of our knowl-
edge only one case of primary anaplastic PXA has been reported
to have an earlier recurrence at 1 month (Kim et al., 2009) [12].
The average recurrence interval as per our literature review was
approximately 14 months from the time of initial diagnosis. The
APXA lesion was  found to be mostly located in temporal and pari-
etal lobes in most of the cases. It showed similar pattern involving
the medial temporal lobe and para sylvian ﬁssure in the afore-
mentioned case description. Previous studies have shown presence
of neuroglial tumor markers like GFAP expression with reticulin
CASE  REPORT  –  OPEN  ACCESS
186 U.K. Choudry et al. / International Journal of Surgery Case Reports 27 (2016) 183–188
Fig. 5. E. Immunohistochemistry showing diffuse GFAP staining. F. Negative CD34 staining. G. ki 67 staining showing diffuse proliferative index of 8–10% and presence of
increased mitosis (>5–10/hpf).
deposition as it was seen in this case [23]. Our inference about
behavior of PXA as an anaplastic tumor stems from the fact that
tumor showed proliferative index of 8–10% in some areas, which
along with the presence of increased mitoses (>5/10hpf) corre-
sponded to WHO  grade III classiﬁcation of diffuse astrocytomas
[15]. Previously reported cases of APXA also have shown similar
histological characteristics (Table 2). It was seen that presence of
pleomorphism was a consistent feature in majority of the cases.
The APXA tissue sections show bizarre giant cells that are multi-
nucleated or have multilobulated nuclei, with intracytoplasmatic
lipid-containing vacuoles (xanthic), and are generally organized in
alveolar structures, with an abundant surrounding reticulin net-
work and perivascular lymphoid inﬁltrates. In contrast to benign
PXA, the anaplastic variants have consistently shown high mitotic
activity along with areas of focal necrosis in most of the cases. Long
term control of anaplastic PXA with recurrences has been attributed
to postsurgical stereotactic radiation therapy (Koga, Tomoyuki, et
al) [13]. However due to its unavailability in our facility we  planned
to provide external beam radiation therapy for long term pallia-
tive control of tumor. According to the current review of literature
the most commonly used treatment option was surgical excision
and post surgical radiotherapy. Complete surgical excision is still an
effective treatment in benign PXA with excellent 5 year and 10 year
survival rates; however, we found that gross total resection in APXA
is still associated with frequent recurrences. Previously there was
no sufﬁcient literature supporting the role of chemotherapy in the
treatment of pleomorphic xanthoastrocytomas in adults, recent
studies have shown the role of BRAF V600E inhibitors in treatment
of PXA tumors pertaining to the high frequency of these mutations
in PXA tumors [22]. Due to the lack of BRAFV600E testing in our
facility, no chemotherapy was planned for this patient. The average
survival in months among the reported APXA cases was approxi-
mately 24 months from the time of initial diagnosis according to
our case review (Table 1). This indicates a relatively poor prognosis
in patients with anaplastic PXA tumor at the initial presentation
when compared with the benign PXA tumors in adults [19].
4. Conclusion
Our review of all reported cases of APXA in adults concludes
that the clinical behavior of this tumor varies considerably from
its benign variant. As per this review of literature it is seen that
anaplastic variant of PXA shows histological characteristics as well
as clinical course comparable with Grade III astrocytomas. Early
disease recurrence in anaplastic pleomorphic xanthoastrocytomas
is associated with fatal outcomes.
We recommend further evaluation of PXA with anaplastic fea-
tures regarding their genetic characteristics to understand the
origin as well as behavior of this tumor.
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Table  1
Review of previously reported primary anaplastic Pleomorphic xanthoastrocytoma cases in adults.
Author (Date) Age/sex Site Treatment Recurrence
Interval
(months)
Net survival
(months)
Goldring et al.
[7]
24/female Temporal lobe Surgery + chemotherapy 12 months 12 months
Iwaki et al. [9] 30/male Parieto-
occipital
sulcus
Surgery + radiotherapy 6 months 10 months
Perry  et al. [21] 18/male Temporal lobe Surgery + radiotherapy + chemotherapy Multiple
recurrences
48 months
Tonn et al. [23] 18/male Temporal + occipital
lobe
Surgery + radiotherapy + chemotherapy 8 months 30 months
Chakrabarty
et  al. [3]
49/male
40/male
Temporal + occipital
lobe
Temporal lobe
Surgery + radiotherapy
Surgery + radiotherapy
Not reported
Not reported
Not reported
Not reported
Buccerio et al.
[2]
65/male Thalamic Surgery + Radiotherapy 22 months 22 months
Zhuang et al.
[25]
53/female Frontal lobe Surgery + radiotherapy + chemotherapy Not reported 24 months
Gelpi et al. [5] 43/female Occipital lobe Surgery + Radiotherapy 36 months Alive
Asano  et al. [1] 59/female Temporal lobe Surgery Not reported 36 months
Marton et al.
[16]
40/female Temporal lobe Surgery 30 months 30 months
Hirose et al. [8] 52/male
39/female
25/male
Frontal lobe
Frontal + Temporal
lobe
Cerebellum
Surgery
Surgery + radiotherapy + chemotherapy
Surgery
Not reported
Not reported
Not reported
Alive
Not reported
Not reported
Kim  et al. [12] 45/male Temporal lobe Surgery 1 month 17 months
Koga et al. [13] 47/female Frontal lobe Surgery + Radiotherapy Not reported Not reported
Frank  et al. [4] 28/male Temporal lobe Surgery + radiotherapy + chemotherapy 14 months Not reported
Lacoste-Collin
et  al. [14]
45/female Peri ventricular Biopsy only Not reported Not reported
Nern,  Christian
et al. [18]
57/male Temporal lobe Surgery + radiotherapy + chemotherapy 10 months 12 months
Kosuke, et al.
[10]
61/female Pineal Gland Surgery + radiotherapy + chemotherapy Not reported Alive
Montano el al.
[17]
22/male Parietal
lobe + Temporal
lobe
Surgery + radiotherapy + chemotherapy Not reported Alive
Usama  et al.
(Present study)
53/male Temporal
lobe + sylvian
Surgery + Radiotherapy 2 months 4 months
Table 2
Comparison of histological features of previously reported Anaplastic PXA tumors with the present study. (Mitosis; 0–2 cells/hpf = +; 3–5 cells/hpf = ++; 5–10 cells/hpf = ++ + ).
Author Pleomorphism Eosinophilic hyaline globules Nuclear inclusions Xanthomatous cells Mitosis Spindle cells Necrosis GFAP
Iwaki et al. [9] + + + +++ +
Perry et al. [21] + +++ +
Tonn  et al. [23] + + + + +
Buccerio et al. [2] + + + + + +
Asano  et al. [1] + + + +++ + +
Marton et al. [16] + + + +++ +
Hirose  et al. [8] + + + + + + + + + + + + + + + + +
Kim  et al. [12] + + ++ +
Koga  et al. [13] + + + + +
Frank  et al. [4] + + + + +
Lacoste-Collin et al. [14] + + + +++ +
Nern,  Christian et al. [18] + + ++ + +
Kosuke, et al. [10] + + + +
Usama et al. (Present study) + + + + +++ + + +
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